Cell Reports (Jul 2016)

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML

  • Naidu M. Vegi,
  • Josef Klappacher,
  • Franz Oswald,
  • Medhanie A. Mulaw,
  • Amit Mandoli,
  • Verena N. Thiel,
  • Shiva Bamezai,
  • Kristin Feder,
  • Joost H.A. Martens,
  • Vijay P.S. Rawat,
  • Tamoghna Mandal,
  • Leticia Quintanilla-Martinez,
  • Karsten Spiekermann,
  • Wolfgang Hiddemann,
  • Konstanze Döhner,
  • Hartmut Döhner,
  • Hendrik G. Stunnenberg,
  • Michaela Feuring-Buske,
  • Christian Buske

DOI
https://doi.org/10.1016/j.celrep.2016.05.094
Journal volume & issue
Vol. 16, no. 2
pp. 498 – 507

Abstract

Read online

Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.